TWINWIZ, a Korean developer of liquid antimicrobial, antiviral, and antifungal materials, announced that it has secured investment from the ‘IBK Changgong Bisang 2 Fund,’ formed by CNTTech. The investment amount was not disclosed.

Founded in 2022 as a materials research company, TWINWIZ has grown into a specialized firm in liquid antimicrobial, antiviral, and antifungal materials. The company has successfully commercialized material technologies that impart these functionalities to products across various industries and daily life without altering color, appearance, or physical properties. Additionally, its technology can be applied without additional processes or equipment, offering convenience to clients and enabling rapid value creation. Last October, TWINWIZ relocated and expanded its facilities, laying the groundwork for further growth.

Regarding this investment, Hwa-seong Jeon, CEO of CNTTech, stated, “We believe TWINWIZ’s innovative material technology will play a crucial role in future markets shaped by post-COVID-19 trends, climate change, and aging populations. We expect the company to create meaningful value in the advanced materials industry.”

Chang-soo Kim, CEO of TWINWIZ, shared his vision, saying, “We recently signed supply contracts with global advanced materials companies such as Toray Advanced Materials and JKP Paint. With this investment, we will strengthen our competitive edge as a leading antimicrobial materials company and aim to become a globally recognized materials enterprise.”